RxDoctor Payments DataLook up a doctor →

Clayton Blehm, MD

Ophthalmology · Gainesville, GANPI 1235127713

Payments from drug & device makers

$1,714,244in general payments, 2019–2025

Across 294 payments — averaging $5830.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$1.7M
  • Topcon Healthcare, Inc.$19K
  • Alcon$18K
  • Sun Pharmaceutical Industries Inc.$4K
  • Bausch & Lomb Americas Inc.$4K
  • AbbVie$693
  • plus $3K from 22 others
$441,500in research payments, 2019–2025

Across 10 payments — averaging $44,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$442K

What the payments were for

  • Consulting fees$25,83662%
  • Speaking & faculty fees$3,97610%
  • Travel & lodging$2,2745%
  • Food & beverage$9,18322%
  • Education$2471%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,714,244 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$571,664
Medicare patients
1,112
Services billed
3,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$36,463
LumiganBimatoprost43$28,418
XiidraLifitegrast12$17,699
RocklatanNetarsudil Mesylat/Latanoprost30$12,812
Latanoprost688$10,275
Travoprost45$9,519
Cyclosporine15$7,955
Brimonidine Tartrate119$4,922
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$4,512
SimbrinzaBrinzolamide/Brimonidine Tart21$4,293
CombiganBrimonidine Tartrate/Timolol12$4,266
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat173$3,375
Timolol Maleate182$2,121
Dorzolamide Hcl101$1,657
Prednisolone Acetate42$1,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$693$69,14779 claims
Bausch & Lomb Americas Inc.Xiidra$3,538$17,69912 claims
Aerie Pharmaceuticals, Inc.Rocklatan$51$12,81230 claims
AlconSimbrinza$18,265$4,29321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →